Dexcom (DXCM) Other Accumulated Expenses (2011 - 2026)

Dexcom (DXCM) has reported Other Accumulated Expenses for 16 consecutive years, with $43.4 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Other Accumulated Expenses rose 1.88% year-over-year to $43.4 million; the TTM figure through Jun 2026 stood at $43.4 million (up 1.88% YoY), while the FY2025 annual figure was $45.8 million, up 23.45% from the prior year.
• Other Accumulated Expenses fell to $43.4 million in Q2 2026 per DXCM's latest filing, from $48.5 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $62.9 million in Q1 2022 and bottomed at $36.7 million in Q3 2024.
• Historically, Other Accumulated Expenses has averaged $45.0 million across 5 years, with a median of $44.6 million in 2025.
• On a YoY basis, Other Accumulated Expenses climbed as much as 41.67% in 2022 and fell as far as 27.29% in 2022.
• Dexcom's Other Accumulated Expenses stood at $39.7 million in 2022, then increased by 2.02% to $40.5 million in 2023, then declined by 8.4% to $37.1 million in 2024, then rose by 23.45% to $45.8 million in 2025, then retreated by 5.24% to $43.4 million in 2026.
• Business Quant data shows DXCM's Other Accumulated Expenses at $43.4 million in Q2 2026, $48.5 million in Q1 2026, and $45.8 million in Q4 2025.